EPISODE · Nov 3, 2020 · 21 MIN
Individualizing COPD Treatment Using the GOLD Guidelines
from Pri-Med Podcasts · host Pri-Med
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/gsk-cme-copd-2 Overview: Join pulmonologist Dr. Matthew Drake as he discusses the current 2020 GOLD guidelines for treatment of COPD. Using patient case examples, he will outline how to assess patients with COPD to determine the most appropriate evidence-based treatment. Discussion will include which patients will benefit most from inhaled corticosteroids and when to consider triple inhaled therapy with combination of long-acting beta-2-agonist, long acting muscarinic antagonist and inhaled corticosteroids. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 10/9/2020 and they are subject to change as new information is published. Guest: Matthew G. Drake, MD
What this episode covers
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/gsk-cme-copd-2 Overview: Join pulmonologist Dr. Matthew Drake as he discusses the current 2020 GOLD guidelines for treatment of COPD. Using patient case examples, he will outline how to assess patients with COPD to determine the most appropriate evidence-based treatment. Discussion will include which patients will benefit most from inhaled corticosteroids and when to consider triple inhaled therapy with combination of long-acting beta-2-agonist, long acting muscarinic antagonist and inhaled corticosteroids. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 10/9/2020 and they are subject to change as new information is published. Guest: Matthew G. Drake, MD
NOW PLAYING
Individualizing COPD Treatment Using the GOLD Guidelines
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m